Literature DB >> 8011180

Skin sensitivity and transdermal drug delivery. A review of the problem.

A J Carmichael1.   

Abstract

Transdermal devices are now marketed for the delivery of systemic medication through the skin. Advantages associated with transdermal drug delivery include avoidance of first-pass metabolism and improved patient compliance. Drugs currently available by this route include scopolamine (hyoscine), nitroglycerin (glyceryl trinitrate), estradiol, nicotine and clonidine. This novel development has brought in its wake a specific constellation of skin sensitivity problems, which vary widely in incidence between drugs. Varying the site of drug administration to minimise these reactions is important. Any eczematous reaction can be treated with a moderately potent topical steroid. Tolerance to oral challenge in those with topical sensitivity occurs, but caution is still advocated before proceeding to this step. The increasing use of transdermal drug delivery systems across many specialties means that problems of skin sensitivity are of growing relevance to the dermatologist, the hospital specialist and the primary care physician.

Entities:  

Mesh:

Year:  1994        PMID: 8011180     DOI: 10.2165/00002018-199410020-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  58 in total

1.  Allergic contact dermatitis secondary to nitroglycerin in Nitro-Bid ointment.

Authors:  C Zugerman; T Zheutlin; R Giacobetti
Journal:  Contact Dermatitis       Date:  1979-07       Impact factor: 6.600

2.  Contact dermatitis due to nitroglycerin ointment.

Authors:  A A Hendricks; G W Dec
Journal:  Arch Dermatol       Date:  1979-07

3.  The hazards of defibrillation through nitroglycerin patches.

Authors:  K Wrenn
Journal:  Ann Emerg Med       Date:  1990-11       Impact factor: 5.721

4.  Dermatitis due to transdermal therapeutic systems.

Authors:  A A Fisher
Journal:  Cutis       Date:  1984-12

5.  Clinical acceptability of transdermal clonidine: a large-scale evaluation by practitioners.

Authors:  J Hollifield
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

6.  Allergic contact dermatitis secondary to topical nitroglycerin.

Authors:  W F Sausker; F D Frederick
Journal:  JAMA       Date:  1978-04-28       Impact factor: 56.272

Review 7.  Transdermal drug delivery: a review of pharmaceutics, pharmacokinetics, and pharmacodynamics.

Authors:  L Moore; Y W Chien
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1988       Impact factor: 4.889

8.  Allergic contact dermatitis secondary to transdermal nitroglycerin.

Authors:  A S Rosenfeld; W B White
Journal:  Am Heart J       Date:  1984-10       Impact factor: 4.749

Review 9.  A review of contact dermatitis associated with transdermal therapeutic systems.

Authors:  M R Holdiness
Journal:  Contact Dermatitis       Date:  1989-01       Impact factor: 6.600

10.  Severe allergic contact dermatitis secondary to nitroglycerin in a transdermal therapeutic system.

Authors:  O Topaz; D Abraham
Journal:  Ann Allergy       Date:  1987-11
View more
  4 in total

Review 1.  Use of transdermal drug formulations in the elderly.

Authors:  Laure-Zoé Kaestli; Anne-Florence Wasilewski-Rasca; Pascal Bonnabry; Nicole Vogt-Ferrier
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Transdermal clonidine skin reactions.

Authors:  L Michael Prisant
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Mar-Apr       Impact factor: 3.738

3.  Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery.

Authors:  Fatima Ramzan Ali; Muhammad Harris Shoaib; Rabia Ismail Yousuf; Syed Abid Ali; Muhammad Suleman Imtiaz; Lubna Bashir; Shazia Naz
Journal:  Biomed Res Int       Date:  2017-09-27       Impact factor: 3.411

4.  Transdermal clonidine: therapeutic considerations.

Authors:  Domenic A Sica; Rebecca Grubbs
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-09       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.